172 related articles for article (PubMed ID: 32467337)
21. Efficacy and safety of sirolimus in lymphangioleiomyomatosis.
McCormack FX; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Young LR; Kinder BW; Downey GP; Sullivan EJ; Colby TV; McKay RT; Cohen MM; Korbee L; Taveira-DaSilva AM; Lee HS; Krischer JP; Trapnell BC; ;
N Engl J Med; 2011 Apr; 364(17):1595-606. PubMed ID: 21410393
[TBL] [Abstract][Full Text] [Related]
22. Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.
Makovski V; Jacob-Hirsch J; Gefen-Dor C; Shai B; Ehrlich M; Rechavi G; Kloog Y
Cell Death Dis; 2014 Dec; 5(12):e1557. PubMed ID: 25476905
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.
Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
Chest; 2018 Jan; 153(1):124-132. PubMed ID: 28533049
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor.
Evans JF; Rue RW; Mukhitov AR; Obraztsova K; Smith CJ; Krymskaya VP
Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31878201
[TBL] [Abstract][Full Text] [Related]
25. Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis.
Taveira-DaSilva AM; Moss J
Clin Epidemiol; 2015; 7():249-57. PubMed ID: 25897262
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis: Progress and Future Directions.
Liu HJ; Krymskaya VP; Henske EP
Chest; 2019 Dec; 156(6):1062-1067. PubMed ID: 31437431
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
Mou Y; Ye L; Wang J; Yee MS; Song YL; Zhu L; Jin ML
Lymphology; 2016 Sep; 49(3):140-9. PubMed ID: 29906075
[TBL] [Abstract][Full Text] [Related]
28. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
29. Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors.
Alayev A; Salamon RS; Sun Y; Schwartz NS; Li C; Yu JJ; Holz MK
Am J Respir Cell Mol Biol; 2015 Nov; 53(5):637-46. PubMed ID: 25844891
[TBL] [Abstract][Full Text] [Related]
30. EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.
Taveira-DaSilva AM; Moss J
Expert Opin Orphan Drugs; 2016; 4(4):369-378. PubMed ID: 27833825
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.
Gupta N; Lee HS; Young LR; Strange C; Moss J; Singer LG; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Taveira-DaSilva AM; Krischer JP; Setchell K; Trapnell BC; Inoue Y; McCormack FX;
Eur Respir J; 2019 Apr; 53(4):. PubMed ID: 30846465
[TBL] [Abstract][Full Text] [Related]
32. Lymphangioleiomyomatosis: a clinical update.
McCormack FX
Chest; 2008 Feb; 133(2):507-16. PubMed ID: 18252917
[TBL] [Abstract][Full Text] [Related]
33. Durability of Sirolimus for Lymphangioleiomyomatosis.
Martirossian A; Shah S; Carrete L; Valle J; Valentine V
Am J Med Sci; 2017 Dec; 354(6):603-607. PubMed ID: 29208258
[TBL] [Abstract][Full Text] [Related]
34. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis.
Hirose M; Matsumuro A; Arai T; Sugimoto C; Akira M; Kitaichi M; Young LR; McCormack FX; Inoue Y
PLoS One; 2019; 14(2):e0212776. PubMed ID: 30818375
[TBL] [Abstract][Full Text] [Related]
35. Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.
Lamattina AM; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Cui Y; Rosas IO; Moss J; Henske EP; El-Chemaly S
Chest; 2018 Nov; 154(5):1070-1082. PubMed ID: 30144422
[TBL] [Abstract][Full Text] [Related]
36. The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis.
Gao N; Zhang T; Ji J; Xu KF; Tian X
Orphanet J Rare Dis; 2018 Aug; 13(1):134. PubMed ID: 30107845
[TBL] [Abstract][Full Text] [Related]
37. Management of lymphangioleiomyomatosis.
Taveira-DaSilva AM; Moss J
F1000Prime Rep; 2014; 6():116. PubMed ID: 25580270
[TBL] [Abstract][Full Text] [Related]
38. A survey of use of mTOR inhibitors in patients with lymphangioleiomyomatosis listed for lung transplant.
Warrior K; Leard LE; Nair AR; Gries CJ; Fisher AJ; Johnson SR; McCormack FX; Dilling DF
Respir Med; 2022; 195():106779. PubMed ID: 35276437
[TBL] [Abstract][Full Text] [Related]
39. Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center.
Amaral AF; de Oliveira MR; Dias OM; Arimura FE; Freitas CSG; Acencio MMP; de Alvarenga VA; Kairalla RA; Carvalho CRR; Baldi BG;
Lung; 2019 Apr; 197(2):139-146. PubMed ID: 30623243
[TBL] [Abstract][Full Text] [Related]
40. Lymphangioleiomyomatosis: differential diagnosis and optimal management.
Xu KF; Lo BH
Ther Clin Risk Manag; 2014; 10():691-700. PubMed ID: 25187723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]